Researchers at King's College London have developed IgE antibodies targeting HER2-expressing cancers. Early studies show ...

Novel HER2 therapies show strong intracranial efficacy, enabling systemic treatment over local therapy for small, ...

Dr. Kevin Kalinsky covers the gamut of the current treatment landscape for patients with HER2-negative breast cancer, ...

The first patients have been enrolled in the HEROES trial, exploring de-escalation of anti-HER2 therapy in metastatic HER2+ ...

Immunotherapy, or antibody treatment that activates the patient's own immune system against cancer, is increasingly being ...

Vepdegestrant is a novel proteolysis targeting chimera protein degrader designed to target and degrade the estrogen receptor.

ER+/PR+ breast cancer, common and hormone-responsive, offers a better prognosis and is key in treatment research advancements ...

Metastatic breast cancer is complex, requiring holistic care and ongoing treatment, with varying prognosis depending on ...

Final part of treatment is medical therapy. And for HER2-negative breast cancer, there are multiple different categories of medical therapy. If the tumor is bigger, if it has genes that are ...

New agents targeting endocrine therapy and CDK4/6 resistance in hormone receptor–positive breast cancer are in development.

Accepted for Priority Review Zongertinib (Boehringer Ingelheim) Tyrosine kinase inhibitor that selectively blocks HER2 Treatment of adult patients with unresectable or metastatic non-small cell ...

VERITAC-2 achieved its primary endpoint in the estrogen receptor 1-mutant population, demonstrating statistically significant and clinically ...